Finance

Lists
Why is ANW down 10,26%?
Dive Deeper
ANW:FRA
Immuron Ltd
0,018 €
-10,26%
(-0,0020) 1D
14 қаз., 22:00:00 GMT+2  ·   EUR
All symbols
SymbolPriceChange% Change
Generating top insights for ANW...
Open
0,02 €
High
0,02 €
Low
0,02 €
Mkt. cap
9,35 млн
Avg. vol.
904,00
Volume
0,00
52-wk high
0,04 €
52-wk low
0,01 €
No. of employees
8
Open
0,02 €
High
0,02 €
Low
0,02 €
Mkt. cap
9,35 млн
Avg. vol.
904,00
Volume
0,00
52-wk high
0,04 €
52-wk low
0,01 €
No. of employees
8
News stories
From web sources and news partners
Profile
Immuron is a biotechnology company based in Melbourne, Australia. In 2008, the company changed its name to Immuron Limited, having previously operated as Anadis Limited. Immuron is focused on antigen-primed and dairy-derived health products. Its proprietary technologies allow for rapid development of polyclonal antibody and other proteins-based solutions for a range of diseases. The company specialises in nutraceutical, pharmaceutical and therapeutic technology products for conditions such as oral and GI mucositis, avian influenza, E. coli travellers' diarrhoea and Anthrax containment. In 2005, Anadis signed an agreement with Quebec's Baralex Inc. and Valeo Pharma Inc. for the distribution of Travelan, a product made by Anadis for the Canadian market. Wikipedia
About Immuron Ltd
CEO-
Employees8
Founded1994
HeadquartersBlackburn North, Victoria, Австралия
Sector-
Previous reportsAll values in AUD
Loading Previous Earnings...
Revenue
Net income
All values in AUD
2025 ж. қыр.
2025 ж. жел.
2026 ж. нау.
2026 ж. мау.
Revenue
2,09 млн
2,09 млн
1,76 млн
1,76 млн
Cost of goods sold
765,33 м.
765,33 м.
603,93 м.
603,93 м.
Cost of revenue
765,33 м.
765,33 м.
603,93 м.
603,93 м.
Research and development expenses
589,74 м.
589,74 м.
376,98 м.
376,98 м.
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
1,89 млн
1,89 млн
2,00 млн
2,00 млн
Operating expense
2,31 млн
2,31 млн
1,96 млн
1,96 млн
Total operating expenses
3,08 млн
3,08 млн
2,56 млн
2,56 млн
Operating income
-986,57 м.
-986,57 м.
-796,24 м.
-796,24 м.
Other non operating income
-
-
-
-
EBT including unusual items
-959,54 м.
-959,54 м.
-880,46 м.
-880,46 м.
EBT excluding unusual items
-959,54 м.
-959,54 м.
-880,46 м.
-880,46 м.
Income tax expense
-
-
-
-
Effective tax rate
-
-
-
-
Other operating expenses
-167,08 м.
-167,08 м.
-417,86 м.
-417,86 м.
Net income
-959,54 м.
-959,54 м.
-880,46 м.
-880,46 м.
Net profit margin
-45,86%
-45,86%
-49,90%
-49,90%
Earnings per share
-
-
-
-
Interest and investment income
30,32 мың
30,32 мың
62,40 мың
62,40 мың
Interest expense
-3,29 мың
-3,29 мың
-4,06 мың
-4,06 мың
Net interest expenses
27,03 мың
27,03 мың
58,33 мың
58,33 мың
Depreciation and amortization charges
-
-
-
-
EBITDA
-974,15 м.
-974,15 м.
-783,82 м.
-785,66 м.
Gain or loss from assets sale
-
-
-
-
AI content may include mistakes. Learn more
Google қолданбалары